ATYPICAL UREMIC HEMOLYTIC SYNDROME (SHUA) AFTER KIDNEY TRANSPLANTATION

Authors

DOI:

https://doi.org/10.5281/jrg.v3i7.32

Keywords:

Atypical Hemolytic Uremic Syndrome. Thrombotic microangiopathy. Eculizumab.

Abstract

Hemolytic uremic syndrome (HUS) is a disease that belongs to the group of thrombotic microangiopathies1, a serious disease defined by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. It is divided into two subtypes, the typical SHU and the atypical SHU (SHUa). This division is based on the clinical presentation and, mainly, on the causes of the syndrome. The aim of this study was to identify cases of recurrence of Atypical Hemolytic Uremic Syndrome after Kidney Transplantation. This is an integrative review of a qualitative approach, carried out from August 2019 to June 2020. References were sought such as: Scientific Eletronic Library Online, Brazilian Journal of Nephrology, Ministry of Health, MEDLINE and BDENF, where they were researched and studied 22, of which 6 were more relevant to the development of this work. The results of the study demonstrate that although it is considered a serious disease, there are few studies carried out on HUSA, and with a long period of time between publications, however the recurrence of HUSA after renal transplantation requiring drug treatment with Eculizumab is concluded. throughout life.

Downloads

Download data is not yet available.

Author Biographies

Thamara Cardoso Barbosa, FACESA-Faculdade de Ciências e Educação Sena Aires, FACESA, Brasil.

Lattes: http://lattes.cnpq.br/3308612636208059
Orcid: https://orcid.org/0000-0003-3149-7446

Mariellen da Silva Caixeta, FACESA-Faculdade de Ciências e Educação Sena Aires, FACESA, Brasil.

Orcid: https://orcid.org/0000-0002-1131-4086

Walquiria Lene dos Santos, FACESA-Faculdade de Ciências e Educação Sena Aires, FACESA, Brasil.

Lattes: http://lattes.cnpq.br/4723603129713855
Orcid: https://orcid.org/0000-0001-6489-5243
E-mail: walquiria@senaaires.com.br

Alice da Cunha Morales Álvares, FACESA-Faculdade de Ciências e Educação Sena Aires, FACESA, Brasil.

Orcid: https://orcid.org/0000-0002-0444-1319

Lattes: http://lattes.cnpq.br/5367332853652325

References

Eculizumab na Síndrome Hemolítica ­ Urêmica Atípica.;62–82.Yvoty A. S. Sens, Luiz A. Miorin, Hélio G. C. Silva, Pedro Jabur Faculdade de Ciências Médicas da Santa Casa de São Paulo. 2017.

SOUSA D. Síndrome Hemolítica Urémica Atípica.;30. Available from: https://sigarra.up.pt/fmup/pt/pub_geral.show_file?pi_gdoc_id=626330 Instituto de Ciências Biomédicas Abel Salazar- Universidade do Porto, Portugal. 2014.

DRIELLY M. S. Ferreira; Carlos Pereira Nunes Eculizumab para tratamento da síndrome hemolítica urêmica atípica. Revista da Faculdade de Medicina de Teresópolis V.1 | N.1.2017.

TOMÁS D, Luís A, Dra O, Santos J. O papel do Sistema Complemento no Síndrome Hemolítico Urémico Atípico.; Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Portugal. 2014.

SENS YAS, Miorin LA, Silva HGC, Jabur P. Revisão / Atualização em Transplante Renal : Síndrome Hemolítico- Urêmica pós-transplante renal Síndrome Hemolítico-Urêmica.20 (2):211–4. 1998.

NEFROLOGIA SB De. Um novo biênio, uma nova diretoria à frente da SBN; Publicação Oficial da Sociedade Brasileira de Nefrologia Ano 25 | nº 116 Outubro Novembro Dezembro | 2018.

Published

2020-07-13

How to Cite

BARBOSA, T. C. .; CAIXETA, M. da S. .; SANTOS, W. L. dos .; ÁLVARES, A. da C. M. . ATYPICAL UREMIC HEMOLYTIC SYNDROME (SHUA) AFTER KIDNEY TRANSPLANTATION. JRG Journal of Academic Studies, Brasil, São Paulo, v. 3, n. 7, p. 01–09, 2020. DOI: 10.5281/jrg.v3i7.32. Disponível em: https://revistajrg.com/index.php/jrg/article/view/32. Acesso em: 3 jul. 2024.